title: Neuromyelitis optica.
abstract: Neuromyelitis optica (NMO) is an uncommon central nervous system demyelinating disease that produces transverse myelitis and optic neuritis. Although commonly misdiagnosed as multiple sclerosis, a number of features can help differentiate the two entities, including the presence of NMO-IgG. Immunosuppressants are used to treat NMO, but the overall prognosis is poor.
authors.affiliation: William Penn Life Insurance Company of New York, 100 Quentin Roosevelt Blvd, Garden City, NY 11530, USA. rfeingold@gamerica.com
authors.forename: Robert M
authors.initials: RM
authors.lastname: Feingold
mesh_terms: D000367:Age Factors; D001323:Autoantibodies / Q000097:blood; D015415:Biomarkers / Q000097:blood; D003937:Diagnosis, Differential; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000175:diagnosis; D009471:Neuromyelitis Optica / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology; D011379:Prognosis; D012008:Recurrence; D012737:Sex Factors
chemical_list: D001323:Autoantibodies; D015415:Biomarkers; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents